Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348005 | 0.84 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1AHRMEN1 | |
| SCHEMBL16363804 | 0.83 | SMN1; SMN2 (0.60) | RAB9ASMN1; SMN2NPC1AHRMEN1 | |
| SCHEMBL3064450 | 0.83 | SMN1; SMN2 (0.60) | RAB9ASMN1; SMN2NPC1AHRMEN1 | |
| SCHEMBL10264545 | 0.82 | SMN1; SMN2 (0.67) | RAB9ASMN1; SMN2NPC1AHRMEN1 | |
| SCHEMBL17191015 | 0.81 | MAOB (0.56) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3663859 | 0.81 | APP (0.50) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL11546092 | 0.81 | SMN1; SMN2 (0.68) | RAB9ASMN1; SMN2NPC1AHRMEN1 | |
| SCHEMBL9969534 | 0.80 | SMN1; SMN2 (0.63) | RAB9ASMN1; SMN2NPC1AHRMEN1 | |
| SCHEMBL13978380 | 0.79 | RAB9A (0.67) | RAB9ASMN1; SMN2NPC1AHRMEN1 | |
| SCHEMBL10755249 | 0.78 | NPC1 (0.74) | RAB9ASMN1; SMN2NPC1AHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | disclosed |
| US-7026484-B2 | For therapy of cancer | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1363909-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | RAB9A 4811/4885SMN1; SMN2 4883/4885NPC1 1299/4885 |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | RAB9A 4811/4885SMN1; SMN2 4883/4885NPC1 1299/4885 |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | RAB9A 4809/4885SMN1; SMN2 4879/4885NPC1 1384/4885 |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | RAB9A 4811/4885SMN1; SMN2 4883/4885NPC1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.